title: Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--a clinical overview.
abstract: Chronic hepatitis C virus (HCV) infection is highly prevalent and associated with a wide range of hepatic and extrahepatic complications. The treatment landscape for HCV infection has evolved to include regimens without interferon formulations and/or ribavirin. This change simplifies therapy, improves tolerability, and decreases therapy duration, while improving virologic response rates. This article, the first in a series of 3, will provide an overview of the hepatitis C disease state, identify populations at risk for HCV, describe testing recommendations for the diagnosis of HCV infection, and distinguish new and emerging HCV therapies.
authors.affiliation: monicashah23@gmail.com.
authors.forename: Monica
authors.initials: M
authors.lastname: Shah
authors.forename: Zobair M
authors.initials: ZM
authors.lastname: Younossi
authors.forename: Yekaterina
authors.initials: Y
authors.lastname: Opsha
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D008329:Managed Care Programs; D000071066:Patient Reported Outcome Measures
chemical_list: D000998:Antiviral Agents